Milestone Pharmaceuticals In (MIST) 13F Positioning & Ownership Changes (Q2 2026)

MIST ranks #5120 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

MIST is a disclosed holding of Steve Cohen (Point72 Asset Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

MIST is a top-conviction position for Lion Point Capital, LP — at 5.3% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in MIST belongs to Pavaki Capital Management LLC, but the position matters far more to Lion Point Capital, LP, who has 5.3% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Steve Cohen has added to its MIST position for two straight quarters, increasing it by $6.3M to reach $7.3M today.

Jane Street Group, LLC has trimmed its MIST position for two straight quarters, cutting it by $2.3M while still holding $140.7K.

MIST is up 3.5% today, and institutions have been net buyers of $16.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

MIST reported a net loss of $84.0M over the trailing twelve months.

• Not yet profitable — net loss of $84.0M over the trailing twelve months
• Net income declined year over year, from -$55.5M to -$84.0M
• Operating cash flow was negative, using $49.0M in cash
• Current ratio of 8.01x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.72x equity — within a conventional range